Fintel reports that on August 10, 2023, HC Wainwright & Co. reiterated coverage of 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy recommendation.
Analyst Price Forecast Suggests 132.70% Upside
As of August 2, 2023, the average one-year price target for 4D Molecular Therapeutics is 39.65. The forecasts range from a low of 24.24 to a high of $66.15. The average price target represents an increase of 132.70% from its latest reported closing price of 17.04.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for 4D Molecular Therapeutics is 4MM, an increase of 82.14%. The projected annual non-GAAP EPS is -3.70.
What is the Fund Sentiment?
There are 227 funds or institutions reporting positions in 4D Molecular Therapeutics. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to FDMT is 0.10%, a decrease of 19.60%. Total shares owned by institutions increased in the last three months by 8.09% to 31,897K shares. 
The put/call ratio of FDMT is 0.50, indicating a bullish outlook.
What are Other Shareholders Doing?
Bvf holds 4,007K shares representing 9.57% ownership of the company. No change in the last quarter.
Viking Global Investors holds 3,938K shares representing 9.41% ownership of the company. No change in the last quarter.
Deep Track Capital holds 2,278K shares representing 5.44% ownership of the company. In it's prior filing, the firm reported owning 2,657K shares, representing a decrease of 16.63%. The firm decreased its portfolio allocation in FDMT by 35.08% over the last quarter.
Janus Henderson Group holds 1,877K shares representing 4.48% ownership of the company. In it's prior filing, the firm reported owning 1,466K shares, representing an increase of 21.90%. The firm decreased its portfolio allocation in FDMT by 8.48% over the last quarter.
XBI - SPDR(R) S&P(R) Biotech ETF holds 1,250K shares representing 2.99% ownership of the company. In it's prior filing, the firm reported owning 465K shares, representing an increase of 62.82%. The firm increased its portfolio allocation in FDMT by 160.07% over the last quarter.
4D Molecular Therapeutics Background Information
(This description is provided by the company.)
4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP patients, 4D-110 is in a Phase 1 clinical trial for choroideremia patients and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease patients. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
Additional reading:
- 4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights
- 4D MOLECULAR THERAPEUTICS, INC. Dated as of ___________, 20___ [ ] as Trustee
- 4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
- Description of Securities of the Registrant.
- 4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
